中国危重病急救医学
中國危重病急救醫學
중국위중병급구의학
CHINESE CRITICAL CARE MEDICINE
2012年
3期
175-178
,共4页
赵明亮%孙世中%杨细平%涂悦%李建军%马铁柱%张赛
趙明亮%孫世中%楊細平%塗悅%李建軍%馬鐵柱%張賽
조명량%손세중%양세평%도열%리건군%마철주%장새
利奈唑胺%耐甲氧西林葡萄球菌%颅内感染%神经外科术后
利奈唑胺%耐甲氧西林葡萄毬菌%顱內感染%神經外科術後
리내서알%내갑양서림포도구균%로내감염%신경외과술후
Linezolid%Methicillin-resistant Staphylococcus%Intracranial infection%Post neurosurgery
目的 初步评价利奈唑胺治疗神经外科术后患者耐甲氧西林葡萄球菌(MRS)颅内感染的临床疗效及安全性.方法 回顾性总结2009年3月至2011年11月本院神经重症监护病房(NICU)及亚低温治疗中心使用利奈唑胺治疗14例MRS颅内感染患者的资料.于治疗前及治疗7d、14d取血及脑脊液(CSF)培养,进行实验室、病原学和细菌学检查,评估利奈唑胺的临床疗效及不良反应.结果 给予MRS颅内感染患者静脉滴注利奈唑胺治疗14 d后,患者临床症状和CSF化验指标显著好转;CSF葡萄糖(mmol/L)由1.00(0.65)升至3.15(1.60),CSF蛋白定量(mg/L)由2238.50(2072.50)降至606.50(217.30),CSF白细胞数(×106/L)由920.00(1587.50)降至30.00(40.00),CSF中性粒细胞比例>0.20者由14例减少至1例;血清中降钙素原(PCT)水平(μg/L)明显降低并恢复正常[由0.65(1.16)降至0.08(0.09),均P<0.01].临床总有效率为85.7%(12/14),CSF细菌清除率达100%.给予利奈唑胺期间,患者未发生明显不良反应.结论 利奈唑胺能够有效控制MRS颅内感染和缓解炎症反应,疗效明确,具有良好的安全性.
目的 初步評價利奈唑胺治療神經外科術後患者耐甲氧西林葡萄毬菌(MRS)顱內感染的臨床療效及安全性.方法 迴顧性總結2009年3月至2011年11月本院神經重癥鑑護病房(NICU)及亞低溫治療中心使用利奈唑胺治療14例MRS顱內感染患者的資料.于治療前及治療7d、14d取血及腦脊液(CSF)培養,進行實驗室、病原學和細菌學檢查,評估利奈唑胺的臨床療效及不良反應.結果 給予MRS顱內感染患者靜脈滴註利奈唑胺治療14 d後,患者臨床癥狀和CSF化驗指標顯著好轉;CSF葡萄糖(mmol/L)由1.00(0.65)升至3.15(1.60),CSF蛋白定量(mg/L)由2238.50(2072.50)降至606.50(217.30),CSF白細胞數(×106/L)由920.00(1587.50)降至30.00(40.00),CSF中性粒細胞比例>0.20者由14例減少至1例;血清中降鈣素原(PCT)水平(μg/L)明顯降低併恢複正常[由0.65(1.16)降至0.08(0.09),均P<0.01].臨床總有效率為85.7%(12/14),CSF細菌清除率達100%.給予利奈唑胺期間,患者未髮生明顯不良反應.結論 利奈唑胺能夠有效控製MRS顱內感染和緩解炎癥反應,療效明確,具有良好的安全性.
목적 초보평개리내서알치료신경외과술후환자내갑양서림포도구균(MRS)로내감염적림상료효급안전성.방법 회고성총결2009년3월지2011년11월본원신경중증감호병방(NICU)급아저온치료중심사용리내서알치료14례MRS로내감염환자적자료.우치료전급치료7d、14d취혈급뇌척액(CSF)배양,진행실험실、병원학화세균학검사,평고리내서알적림상료효급불량반응.결과 급여MRS로내감염환자정맥적주리내서알치료14 d후,환자림상증상화CSF화험지표현저호전;CSF포도당(mmol/L)유1.00(0.65)승지3.15(1.60),CSF단백정량(mg/L)유2238.50(2072.50)강지606.50(217.30),CSF백세포수(×106/L)유920.00(1587.50)강지30.00(40.00),CSF중성립세포비례>0.20자유14례감소지1례;혈청중강개소원(PCT)수평(μg/L)명현강저병회복정상[유0.65(1.16)강지0.08(0.09),균P<0.01].림상총유효솔위85.7%(12/14),CSF세균청제솔체100%.급여리내서알기간,환자미발생명현불량반응.결론 리내서알능구유효공제MRS로내감염화완해염증반응,료효명학,구유량호적안전성.
Objective To evaluate the efficacy and safety of linezolid in the treatment of post-neurosurgical intracranial methicillin-resistant Staphylococcus(MRS)infection.Methods The data from 14 patients,admitted to neurological intensive care unit(ICU)of Medical College of Chinese People's Armed Police Forces between March 2009 and November 2011,were retrospectively analyzed.All these cases suffered from post-neurosurgical intracranial infection by MRS and received linezolid treatment.Blood and cerebrospinal fluid(CSF)were collected before and 7 days and 14 days after treatment for routine and bacteriological examinations to assess clinical efficacy and adverse reactions of linezolid.Results After 14-day treatment with linezolid,the clinical and laboratory parameters showed significant improvement:glucose(mmol/L)in CSF rose from 1.00(0.65)to 3.15(1.60),protein(mg/L)in CSF dropped from 2238.50(2072.50)to 606.50(217.30),white blood cell count(× 106/L)in CSF fell from 920.00 (1587.50)to 30.00(40.00),and the number of patients with CSF neutrophil ratio>0.20 was reduced from 14 to 1(all P<0.01).In addition,serum procalcitonin level(μg/L)was significantly reduced from 0.65(1.16)to 0.08(0.09)after linezolid therapy(P<0.01).Total effective rate was 85.7%(12/14),and CSF bacterial clearance rate reached 100%.No adverse events were found during the treatment.Conclusion Linezolid could effectively control post-neurosurgical intracranial MRS infection and alleviate the inflammatory responses with safety.